Search
To explore parents' experiences of using continuous glucose monitoring in their young children with early-stage type 1 diabetes, being followed in the Australian Environmental Determinants of Islet Autoimmunity (ENDIA) study.
To assess relationships between continuous glucose monitoring (CGM) time in range (TIR), 70-180 mg/dL, time below range (TBR), <70 mg/dL, time above range (TAR), >180 mg/dL, and glucose coefficient of variation (CV) in relation to currently recommended clinical CGM targets for older people, which recommend reduced TIR and TBR targets relative to the general type 1 diabetes population.
Advanced hybrid closed-loop (AHCL) therapy with the Medtronic MiniMed™ 780G system improves glycemia; however, the clinical outcomes in younger children remain less established. This pilot study aimed to explore the continuous glucose monitoring (CGM) metrics in very young children on AHCL. Children between 2 and 7 years of age and on insulin pump therapy were recruited.
The evidence about the acceptability and effectiveness of innovative paediatric models of care for Type 1 diabetes is limited. To address this gap, we synthesised literature on implemented models of care, model components, outcomes, and determinants of implementation and sustainability.
Read about Professor Tim Jones and Associate Professor Liz Davis, co-directors of the Children's Diabetes Centre.
A new Q&A series focusing on the different research themes within the Children’s Diabetes Centre - technology.
To determine the efficacy of advanced hybrid closed-loop therapy in a high-risk cohort of youth on continuous subcutaneous insulin infusion with or without continuous glucose monitoring with suboptimal glycemia.
The Rio Tinto Children’s Diabetes Centre; a Breakthrough T1D Centre of Excellence at The Kids Research Institute Australia and Perth Children’s Hospital (PCH), is a global hub for research into type 1 diabetes (T1D) in children.
Congratulations to four outstanding early-career researchers from The Kids Research Institute Australia, who have been awarded BrightSpark Foundation fellowships and project funding for 2026.
We know many families have questions about the risk of COVID-19 to children with type 1 diabetes. To address these questions, Perth Children’s Hospital’s Diabetes Clinic has provided information and resources to help you navigate this tricky period.